Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
The study was published in the journal Nature Cell Biology by senior author April Pyle, associate professor of microbiology, immunology and molecular genetics and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore dystrophin, the protein that is missing in the muscles of boys with Duchenne.
Without dystrophin, muscles degenerate and become progressively weaker. Duchenne symptoms usually begin in early childhood; patients gradually lose mobility and typically die from heart or respiratory failure around age 20. There is currently no way to reverse or cure the disease.
For years, scientists have been trying different methods that direct human pluripotent stem cells to generate skeletal muscle stem cells that can function appropriately in living muscle and regenerate dystrophin-producing muscle fibers. However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
“We have found that just because a skeletal muscle cell produced in the lab expresses muscle markers, doesn’t mean it is fully functional,” said Pyle. “For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.”
By analyzing human development, the researchers found a fetal skeletal muscle cell that is extraordinarily regenerative. Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the reserchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Once they were able to isolate skeletal muscle cells using the newly identified surface markers, the research team matured those cells in the lab to create dystrophin-producing muscle fibers. The muscle fibers they created were uniformily muscle cells, but the fibers were still smaller than those found in real human muscle.
“We were missing another key component,” said Michael Hicks, lead author of the study. The skeletal muscle cells were not maturing properly, he explained. “We needed bigger, stronger muscle that also had the ability to contract.”
Once again, the team looked to the natural stages of human development for answers. Hicks discovered that a specific cell signaling pathway called TGF Beta needs to be turned off to enable generation of skeletal muscle fibers that contain the proteins that help muscles contract. Finally, the team tested their new method in a mouse model of Duchenne.
“Our long term goal is to develop a personalized cell replacement therapy using a patient’s own cells to treat boys with Duchenne,” said Hicks. “So, for this study we followed the same steps, from start to finish, that we’d follow when creating these cells for a human patient.”
First, the Duchenne patient cells were reprogrammed to become pluripotent stem cells. The researchers then removed the genetic mutation that causes Duchenne using the gene editing technology CRISPR-Cas9. Using the ERBB3 and NGFR surface markers, the skeletal muscle cells were isolated and then injected into mice at the same time a TGF Beta inhibitor was administered.
“The results were exactly what we’d hoped for,” said Pyle. “This is the first study to demonstrate that functional muscle cells can be created in a laboratory and restore dystrophin in animal models of Duchenne using the human development process as a guide.”
Further research will focus on generating skeletal muscle stem cells that can respond to continuous injury and regenerate new muscle long-term using the team’s new isolation and maturation strategy.
The Latest on: Duchenne Muscular Dystrophy
Human 'chimeric' cells restore crucial protein in Duchenne muscular dystrophy
on March 16, 2018 at 4:40 pm
Cells made by fusing a normal human muscle cell with a muscle cell from a person with Duchenne muscular dystrophy -- a rare but fatal form of muscular dystrophy -- were able to significantly improve muscle function when implanted into the muscles of a ... […]
Muscular Dystrophy Association To Host “Muscle Walk” In Gainesville
on March 15, 2018 at 1:54 pm
The most recent discovery, she said, was Eteplirsen in 2016. Eteplirsen is prescribed to treat a specific strand of Duchenne muscular dystrophy. One of the drug’s primary trails was conducted by the University of Florida. Dr. Barry Byrne, professor and ... […]
Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling
on March 15, 2018 at 11:18 am
The action by the Food and Drug Administration was announced late Wednesday. An adolescent patient with Duchenne muscular dystrophy treated with Solid Bio's gene therapy experienced decreases in platelets and red blood cells. But there were no liver issues ... […]
Shares of Solid Biosciences crater as FDA halts Duchenne gene therapy trial
on March 14, 2018 at 3:28 pm
Less than two months after pulling off one of the biggest initial public offerings for a local biotech in recent years, Cambridge-based Solid Biosciences said that the FDA had halted a trial of its gene therapy treatment for Duchenne muscular dystrophy ... […]
Fred Hutch study paves the way for potential muscular dystrophy treatment
on March 13, 2018 at 4:46 pm
It is the most common form of muscular dystrophy. DMD Therapeutics, a Seattle area startup that spun out of the University of Washington, is pursuing a treatment for a related disease, Duchenne muscular dystrophy. The startup has found success in mice ... […]
Sarepta will seek accelerated approval for 2nd Duchenne muscular dystrophy drug
on March 12, 2018 at 4:43 pm
Sarepta Therapeutics will file an application with the Food and Drug Administration by the end of 2018 seeking accelerated approval for its second drug to treat Duchenne muscular dystrophy, a rare, inherited, muscle-wasting disease. The Cambridge biotech ... […]
Research delivers insight into the Duchenne muscular dystrophy pipeline market review, H1 2018
on March 8, 2018 at 1:54 am
The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2018, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. Duchenne muscular dystrophy (DMD) is a ... […]
Parent Project Muscular Dystrophy to Host Landmark Duchenne Patient-Focused Compass Meeting
on March 5, 2018 at 5:01 am
HACKENSACK, N.J., March 5, 2018 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will host the Duchenne Patient-Focused Compass Meeting ... […]
via Google News and Bing News